Humana (HUM.ST) Stock Price
Humana Price
Revenue has compounded at 10.3% per year over the past 14 years to 10.08 B SEK. Earnings per share have grown at 39.3% per year over the last 14 years. Humana's net margin stands at 2.3%, down from 3.4% several years earlier. Humana currently offers a dividend yield of about 1.41%. The payout ratio is around 21% of earnings. The dividend has grown at 9.1% per year over the past 8 years. Analysts set a median price target of 61.20 SEK, implying 13.8% below the current price. Of 7 analysts, 5 rate the stock a buy — an overall Buy consensus. The stock trades about 80% above its 52-week low.
Humana stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Humana over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Humana stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Humana's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Humana Price |
|---|---|
| 9/2/2026 | 71.00 SEK |
| 9/1/2026 | 71.00 SEK |
| 8/31/2026 | 70.40 SEK |
| 8/28/2026 | 70.80 SEK |
| 8/27/2026 | 71.60 SEK |
| 8/26/2026 | 70.20 SEK |
| 8/25/2026 | 71.70 SEK |
| 8/24/2026 | 71.40 SEK |
| 8/21/2026 | 72.60 SEK |
| 8/20/2026 | 71.40 SEK |
| 8/19/2026 | 69.10 SEK |
| 8/17/2026 | 63.00 SEK |
| 8/14/2026 | 62.70 SEK |
| 8/13/2026 | 62.40 SEK |
| 8/12/2026 | 61.50 SEK |
| 8/11/2026 | 61.80 SEK |
| 8/10/2026 | 62.10 SEK |
| 8/7/2026 | 62.40 SEK |
| 8/6/2026 | 62.90 SEK |
| 8/5/2026 | 62.90 SEK |
| 8/4/2026 | 62.70 SEK |
| 7/31/2026 | 63.00 SEK |
| 7/30/2026 | 63.50 SEK |
| 7/29/2026 | 62.50 SEK |
| 7/28/2026 | 62.20 SEK |
| 7/27/2026 | 62.60 SEK |
| 7/24/2026 | 61.90 SEK |
| 7/23/2026 | 61.80 SEK |
| 7/22/2026 | 62.20 SEK |
| 7/21/2026 | 61.70 SEK |
Humana Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Humana Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB SEK |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEB SEK |
| EBITM SEK |
| EBIT MARGIN% |
| NET INCOMEM SEK |
| NET INCOME GROWTH% |
| DIVIDENDDIV.SEK |
| DIVIDEND GROWTHDIV. GROWTH% |
| SHARESM |
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.07 | 5.66 | 6.36 | 6.56 | 6.73 | 7.47 | 7.80 | 8.19 | 9.24 | 9.65 | 10.30 | 10.08 | 10.28 | 10.66 | 11.01 | 11.47 |
| 43.53 | 11.65 | 12.50 | 3.07 | 2.56 | 11.03 | 4.42 | 5.01 | 12.86 | 4.42 | 6.71 | -2.09 | 2.00 | 3.64 | 3.28 | 4.21 |
| 177.63 | 159.10 | 141.42 | 137.21 | 133.78 | 120.49 | 115.39 | 88.69 | 88.29 | 87.56 | 88.50 | 89.25 | 89.25 | 89.25 | 89.25 | 89.25 |
| 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 7.26 | 8.16 | 8.45 | 9.11 | 9.00 | 9.18 | 9.51 | 9.82 | 10.24 |
| 327.00 | 384.00 | 345.00 | 334.00 | 414.00 | 397.00 | 474.00 | 508.00 | 446.00 | 377.00 | 504.00 | 508.00 | 593.00 | 645.00 | 715.00 | 734.00 |
| 6.46 | 6.79 | 5.42 | 5.09 | 6.16 | 5.32 | 6.08 | 6.20 | 4.83 | 3.91 | 4.90 | 5.04 | 5.77 | 6.05 | 6.50 | 6.40 |
| 38.00 | 28.00 | 148.00 | 194.00 | 246.00 | 188.00 | 262.00 | 276.00 | 210.00 | 176.00 | 144.00 | 236.00 | 265.00 | 306.00 | 359.00 | 374.00 |
| -62.38 | -26.32 | 428.57 | 31.08 | 26.80 | -23.58 | 39.36 | 5.34 | -23.91 | -16.19 | -18.18 | 63.89 | 12.29 | 15.47 | 17.32 | 4.18 |
| – | – | – | 0.50 | 0.60 | 0.70 | – | – | – | – | – | 1.00 | 1.35 | 1.62 | 1.94 | – |
| – | – | – | – | 20.00 | 16.67 | – | – | – | – | – | – | 35.00 | 20.00 | 19.75 | – |
| 45.88 | 45.88 | 51.51 | 53.14 | 53.14 | 53.14 | 52.99 | 48.70 | 47.96 | 47.83 | 50.17 | 49.93 | 49.93 | 49.93 | 49.93 | 49.93 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Humana generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Humana retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Humana's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Humana has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Humana's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Humana stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Humana Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Humana business model & stock analysis
Humana SWOT Analysis
Strengths
Humana AB has several strengths that contribute to its success in the market. Firstly, the company has a strong brand image and reputation, which increases consumer trust and loyalty. Secondly, Humana AB has a wide range of healthcare services and products, allowing it to cater to diverse customer needs. This extensive offering includes primary care, specialist care, and home care services, among others. Additionally, the company has a large network of healthcare professionals, ensuring accessibility and quality care for its customers.
Weaknesses
Despite its strengths, Humana AB also faces certain weaknesses that can hinder its growth. One such weakness is the heavy reliance on government funding for its healthcare programs. This dependence exposes the company to potential changes in government policies or budget cuts. Another weakness is the limited geographical presence of Humana AB, as it primarily operates in a few select regions. This limited reach may hinder its ability to capture a broader market share.
Opportunities
There are several opportunities for Humana AB to explore and expand its business. The growing demand for healthcare services, particularly in the aging population, presents a significant opportunity for the company to increase its market share. Humana AB can leverage its expertise in home care to tap into the expanding market for elderly and chronic care services. Furthermore, the advancement of technology in healthcare, such as telemedicine and digital health solutions, offers Humana AB the opportunity to enhance its service delivery and reach more customers.
Threats
Humana AB also faces various threats that pose risks to its operations and profitability. One major threat is the intense competition within the healthcare industry. Competitors offering similar services and products may attract customers away from Humana AB, reducing its market share. Additionally, regulatory changes in healthcare policies and reimbursement systems can significantly impact the company's financial stability and operations. Lastly, the ongoing COVID-19 pandemic presents a significant threat to Humana AB, as it disrupts normal healthcare practices and imposes additional challenges on service delivery.
Humana Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Humana historical P/E ratio, EBIT multiple, and P/S ratio
Humana annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Humana shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Humana Dividend History
5 years of dividend payments · 3 consecutive increases
Humana dividend history and estimates
3 Years
5 Years
10 Years
25 Years
Max
Details
Humana dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Humana forecasts and price targets in September 2026
Analyst Price Targets 2026Humana Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 2/7/2024 | 0.89SEK | - | 2.46 BSEK | - | 2023 Q4 |
| 2/8/2023 | 1.50SEK | - | 2.44 BSEK | - | 2022 Q4 |
| 11/10/2022 | 2.44SEK | - | 2.37 BSEK | - | 2022 Q3 |
| 8/18/2022 | 1.04SEK | - | 2.23 BSEK | - | 2022 Q2 |
| 2/10/2022 | 1.25SEK | - | 2.12 BSEK | - | 2021 Q4 |
| 8/20/2021 | 1.20SEK | - | 2.11 BSEK | - | 2021 Q2 |
| 5/6/2021 | 1.24SEK | - | 2.03 BSEK | - | 2021 Q1 |
| 2/11/2021 | 0.86SEK | - | 1.97 BSEK | - | 2020 Q4 |
| 11/6/2020 | 1.95SEK | - | 1.97 BSEK | - | 2020 Q3 |
| 8/20/2020 | 0.77SEK | - | 1.98 BSEK | - | 2020 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Humana stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Humana shareholder structure
| % | Name |
|---|---|
2.21516% | |
2.20973% | |
1.06492% | |
0.89414% | |
0.61075% | |
0.59668% |
Humana Beneficial Ownership Filings (SEC 13D/G)
Humana Executives and Management Board
18 members · avg. age 57 · 56 % women
Ms. Nathalie Nilsson (56)
President, Chief Executive Officer
2.56 M SEK
Management
Mr. Christoffer Herou (44)
Chief Financial Officer
Mr. Adam Nerell (48)
Chief Information Officer
Ms. Gabriella Reuterswaerd
Chief Marketing Officer
Ms. Mona Lien (63)
Business Area Manager, Norway
Mr. Titti Lilja (57)
Business Area Manager - Individual and Family
Ms. Leila Rutanen (54)
Country Manager, Finland
Board of Directors
Mr. Anders Nyberg (69)
Independent Chairman of the Board
Mr. Fredrik Stroemholm (60)
Director
Ms. Leena Munter-Ollus (57)
Independent Director
Mr. Ralph Riber (67)
Independent Director
Ms. Carolina Dahl (42)
Director
Ms. Grethe Aasved (71)
Independent Director
Humana Supply Chain
Humana Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.56 | 0.47 | 0.62 | ||
| 2 | Skandinaviska Enskilda Banken A | 0.70 | 0.71 | 0.59 | |
| 3 | 0.37 | 0.45 | 0.44 | ||
| 4 | Nordea Bank Abp | 0.61 | 0.43 | 0.41 |
Frequently asked questions about Humana
The main competitors of Humana AB in the market include companies such as Aleris, Attendo, Ambea, and Capio.
Humana AB is a Swedish company that specializes in providing care and support services for individuals with special needs. Founded in 1993, Humana has grown to become one of the leading companies in the Nordic region, with operations in Sweden, Norway, Finland, Denmark, and Germany. With a strong focus on quality and person-centered care, Humana offers a wide range of services, including housing, home care, and day care. The company is committed to promoting independence, inclusion, and wellbeing for its clients. Over the years, Humana has expanded its services through both organic growth and acquisitions, solidifying its position as a trusted provider in the social care sector.
The business model of Humana AB is focused on providing care and support services to the elderly and individuals with special needs. Through its extensive network of care homes, home care services, and personal assistance, Humana AB aims to ensure that its clients receive the necessary support to maintain their well-being and independence. With a person-centered approach, Humana AB offers customized services tailored to the unique needs of each individual. By offering a range of services such as healthcare, rehabilitation, and social activities, Humana AB strives to enhance the quality of life for those in its care.
Humana AB is primarily active in the healthcare and social services industries.
Humana AB, a premier stock company, has achieved remarkable milestones in its successful journey. With a dedication to excellence, Humana AB has expanded its operations across various sectors, witnessing significant accomplishments over the years. The company has successfully established itself as a leading provider of healthcare and social care services, delivering top-notch quality solutions to its clients. Furthermore, Humana AB has consistently displayed a strong financial performance, demonstrating robust growth and profitability. With its strategic acquisitions and partnerships, Humana AB has expanded its market presence, reinforcing its position as a key player in the industry. Its relentless focus on innovation and customer satisfaction has propelled Humana AB to greater heights, ensuring a bright future ahead.
Humana AB is primarily present in various countries and regions around the world. The company has a strong presence in the Nordic region, including Sweden, Norway, and Finland. It also operates in Europe, with a focus on countries like Germany, the Netherlands, and the United Kingdom. Additionally, Humana AB has expanded its operations to several other countries, such as Russia and Qatar. With its wide geographical footprint, Humana AB has established itself as a prominent player in the healthcare and social services sectors across multiple countries and regions.
Humana AB represents a set of values and corporate philosophy focused on enhancing quality of life and promoting well-being. The company prioritizes the needs and preferences of individuals, offering person-centered care solutions. It aims to provide a safe and inclusive environment where everyone is valued and respected. Humana AB is committed to continuous improvement, innovation, and maintaining high ethical standards in all its operations. The company strives to create positive social impact, championing diversity, sustainability, and social responsibility. Humana AB's dedication to excellence and client satisfaction drives its commitment to delivering exceptional healthcare services and support.
Analysts currently set an average price target of 59.16 SEK for the Humana stock (median: 61.20 SEK), implying -16.7 % versus the latest price. The consensus is based on 7 analyst ratings.
7 analysts currently rate the Humana stock: 5 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Humana to generate revenue of 10.28 B SEK and earnings per share of 5.32 SEK.
Converted at the current exchange rate, the Humana share trades at 6.36 EUR (71.00 SEK).
The Humana share (HUM.ST) is listed on 5 stock exchanges, including: Frankfurt (47H.F), London (0RF7.L), SIX (Zürich) (47H.SW).
Humana AB is a Swedish company that has been active in the fields of care and health for over 60 years. The company's business model is based on various divisions and products tailored to the needs of patients and those in need of care. One of Humana AB's main business areas is patient care. The company provides specialized, comprehensive, and rehabilitative care to patients in Sweden and Finland. In doing so, the company collaborates with various healthcare and social service providers to offer high-quality treatments to patients. Another important area in which Humana AB operates is human resources. The company offers both temporary and permanent employment contracts for healthcare professionals with different specializations. The needs of the caregivers, patients, and healthcare providers are always at the forefront. Among the products offered by Humana AB are incontinence pads and nursing beds. These products are sold to both patients and healthcare and social service providers. The company places great emphasis on quality and follows the latest standards in the care and health industry. Humana AB also focuses on digital transformation and offers a variety of digital solutions. One of these solutions is the "digital assistant," which allows caregivers to remotely monitor important information such as a patient's health condition or medication. This enables the healthcare personnel to quickly respond to new developments in the patient's condition. Overall, Humana AB's business model is characterized by a clear focus on the needs of patients, caregivers, and healthcare and social service providers. The company not only offers specialized services but also provides products and digital solutions to improve patient care and facilitate the work of caregivers. In summary, Humana AB's business model is geared towards constantly improving patient care. The company relies on a healthy balance of traditional services and innovative digital solutions to ensure the best possible patient care.
The expected revenue of Humana is 10.28 B SEK. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Humana is 265.47 M SEK. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Humana is currently 13.35. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Humana stock.
The price-to-sales ratio (P/S) of Humana is currently 0.34. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Humana stock.
The Eulerpool Quality Score for Humana is 4/10.
The ISIN of Humana is SE0008040653. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Humana is A2AFX9. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Humana is HUM.ST. The ticker symbol is used to trade Humana shares on the stock exchange.
Over the past 12 months, Humana paid a dividend of 1.00 SEK . This corresponds to a dividend yield of about 1.41 %. For the coming 12 months, Humana is expected to pay a dividend of 1.62 SEK.
The current dividend yield of Humana is 1.41 %.
Humana pays a dividend, distributed in the months of , , , .
Humana paid dividends every year for the past 1 years.
For the upcoming 12 months, dividends amounting to 1.62 SEK are expected. This corresponds to a dividend yield of 2.28 %.
Humana is assigned to the 'Health' sector.
To receive the latest dividend of Humana from amounting to 1.35 SEK, you needed to have the stock in your portfolio before the ex-date on .
The last dividend was paid out on .
The dividends of Humana are distributed in SEK.
Humana stock
Humana Peer Group
Humana Ticker
Humana FIGI
All fundamentals and in-depth analysis of Humana
Our stock analysis for Humana stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Humana. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.